Where it trades today
trading 81% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The real question is what role this fund should play in allocation construction, not whether one short-term move looks attractive.
- XLV trades at 30.1x earnings, well above the etf average of 20.0x, so the market is already pricing in above-consensus execution.
- XLV should be monitored through portfolio risk contribution because short-term price strength is only useful if it fits the rest of the book.
- Relative performance versus SPY, QQQ, IWM matters here because leadership inside etf rarely stays static for long.
Portfolio Use Case
- XLV fits best as a benchmark or core allocation building block rather than as a thesis that depends on single-company execution.
- The risk profile looks balanced enough for a diversified core-plus portfolio, provided the position size reflects sector concentration.
- This page is most useful for deciding whether the stock deserves a permanent slot in the portfolio or just a place on the watchlist.
What Would Change the View
- A reset in earnings expectations or a faster peer catch-up could compress the premium valuation currently embedded in XLV.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
- There is little income cushion here, so total return depends mainly on price appreciation and execution staying on track.
Methodology
- Price, market cap, beta, yield, and liquidity fields for XLV come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for ETF so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as SPY, QQQ, IWM.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for XLV. Last refresh: Sep 18, 2026, 10:57 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as SPY, QQQ, IWM.
What this fund is
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
What the fund owns
Top 10 Holdings
Sector Allocation
How it sits in etf
Exchange-traded funds offering diversified exposure to various markets and strategies.
The companies it competes with
XLV beside the etf names it is usually measured against.
What the chart is saying
Health Care Select Sector SPDR trades at $168.39, 4.6% below its 52-week high. With a beta of N/A, it shows about average sensitivity to what the wider market does.
Questions people ask about it
Is XLV a good buy right now?
Health Care Select Sector SPDR trades at 30.1x earnings. This is above market average, reflecting growth expectations. Current risk level is Medium based on 19.0% volatility.
Does XLV pay dividends?
Health Care Select Sector SPDR does not currently pay a regular dividend. The company may be reinvesting profits for growth.
How volatile is XLV?
With 30-day annualized volatility of 19.0% and beta of N/A, XLV is classified as Medium risk.